Uncategorized

Amgen continues to defend Tavneos as global regulatory pressure mounts

Published

on

Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the medicine, which was acquired in the $3.7 billion buyout of ChemoCentryx.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version